An in utero exposure to the synthetic estrogen diethylstilbestrol affects the fat pad composition in post-natal mammary glands

Tovar Parra, J. D.; McDermott, A.; Cardot, J.; Juarez, M.; Joao, F.; El Omri-Charai, R.; Berthiaume, L.; Dhawan, B.; Aghigh, A.; Breton, Y.; Legare, F.; Delbes, G.; Pelletier, M.; Audet-Walsh, E.; Plante, I.

doi:10.1101/2025.09.11.675719

bioRxiv · 10.1101/2025.09.11.675719

An in utero exposure to the synthetic estrogen diethylstilbestrol affects the fat pad composition in post-natal mammary glands

Tovar Parra, J. D.·McDermott, A.·Cardot, J.·Juarez, M.·Joao, F.·El Omri-Charai, R.·Berthiaume, L.·Dhawan, B.·Aghigh, A.·Breton, Y.·Legare, F.·Delbes, G.·Pelletier, M.·Audet-Walsh, E.·Plante, I.

View original source ↗Export metadata ↓

Abstract

In utero exposure to the synthetic estrogen diethylstilbestrol (DES) has been linked to developmental abnormalities and elevated breast cancer risk in adulthood in human and rodent models. While the impact of DES on the mammary epithelium has been thoroughly investigated, its effect on the other cell types of the mammary gland remains understudied. Here, given that the mammary gland development is strongly associated with its microenvironment, we aimed to investigate how in utero DES exposure alters the mammary glands stromal and immune function across key developmental stages. To achieve this aim, timed-pregnant rats were gavaged daily with DES or vehicle from gestation days 16-21, and female offspring mammary glands were analyzed at pre-puberty (postnatal day 21 (PDN21)), puberty (PND46), and adulthood (PND90). We assessed morphological and extracellular matrix changes, performed transcriptomic cell-type enrichment analysis, measured cytokine expression, and quantified immune cell populations. DES-exposed mammary glands exhibited pronounced stromal remodeling, including increased collagen deposition and orientation by adulthood. Gene expression profiling indicated DES-induced stage-specific immune alterations: immune cell signatures were enriched at PND21 and PND90 but diminished at PND46. Correspondingly, DES increased macrophage populations at PND21 while reducing T-lymphocyte numbers at PND46 and PND90. DES exposure also dysregulated inflammatory cytokine/chemokine expression in adult glands, suggesting a persistent inflammatory environment. In conclusion, in utero exposure to an estrogenic compound can reprogram mammary development, inducing long-term changes in the extracellular matrix and immune landscape. These disruptions to stromal-immune homeostasis may impair normal mammary morphogenesis and increase susceptibility to breast pathologies later in life.

Source connections

Published article ↗

Explore related subjects

pharmacology and toxicology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Tovar Parra, J. D., McDermott, A., Cardot, J., Juarez, M., Joao, F., El Omri-Charai, R., Berthiaume, L., Dhawan, B., Aghigh, A., Breton, Y., Legare, F., Delbes, G., Pelletier, M., Audet-Walsh, E., Plante, I.. 2025-09-17. An in utero exposure to the synthetic estrogen diethylstilbestrol affects the fat pad composition in post-natal mammary glands. https://doi.org/10.1101/2025.09.11.675719

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

A metastable GαS/β-arrestin complex sustains endosomal PTH1R signaling

G protein-coupled receptors (GPCRs) initiate cellular signaling by activating heterotrimeric G proteins at the plasma membrane and are silenced when beta-arrestin binds the phosphorylated receptor, preventing G protein binding. However, many receptors continue to generate cAMP after internalization, even while barr is bound, a paradox that lacked a molecular mechanism in live cells. A direct barrestin1-Gas interface in the PTH1R-barr1-Gas complex has recently been defined structurally, but whether the complex operates in endosomes, and how it behaves there, has not been established. Using intact cells, we examine the assembly at three spatial resolutions. Confocal imaging with a nanobody selective for nucleotide-free Gas places activated Gas, barr, and agonist-occupied PTH1R on the same endosomes. Single-molecule localization microscopy, with illumination modes that separate the plasma membrane from the endosomal membrane in single cells, shows that the agonist recruits Gas and barr at both membranes. FRET, however, reveals a specific interaction only on endosomes, where a Gas inhibitor restricted to that compartment abolishes the sustained cAMP phase without affecting receptor internalization. Weighted-ensemble-enhanced molecular simulations show that the complex is metastable, releasing Gas through a large rigid-body rotation away from barr while barr itself tightens its interactions with the receptor. These findings provide a molecular basis for endosomal Gs/cAMP signaling and open a new avenue for drug development targeting this pathway.

pharmacology and toxicology↗

bioRxiv2026

Advancing AOPs for genotoxicity through quantifying KERs linking DNA alkylation to increase in mutations and chromosome aberrations

Quantitative Adverse Outcome Pathways (qAOPs) help translate mechanistic knowledge into quantitative toxicity predictions; however, their development is constrained by the limited availability and heterogeneity of quantitative data. Here, we investigated the feasibility of developing a qAOP for genotoxicity by modeling quantitative relationships linking DNA alkylation to increased mutations and structural chromosome aberrations through intermediate biological key events (KEs). We compiled and harmonized published concentration-response data from human lymphoblastoid TK6 cells exposed to ethyl methanesulfonate, methyl methanesulfonate, or N-ethyl-N-nitrosourea, covering eight genotoxicity assays representing five KEs with well-established dependencies. We evaluated sources of variability, compared points of departure (PoDs), and quantified relationships between successive events using response-response modeling. Substantial between-study variability could to a limited extent be explained through differences in experimental design while batch effects for individual studies and researchers were substantial. PoD estimates that were calculated from combined results of independent studies with similar experimental design, were often uncertain due to insufficient concentration-response characterization or conflicting results between studies. Nevertheless, response-response modeling suggested a threshold effect for certain key-event relationships (KERs). Specifically, DNA adducts seemed to be triggered at lower concentrations of alkylating agents compared to the subsequent KEs of DNA strand breaks and chromosome aberrations. Furthermore, these fitted response-response models can be used for prediction of downstream KEs from earlier ones. The general approach we developed for BMC analysis followed by response-response modeling is applicable to other AOPs as well. These findings highlight both the feasibility and limitations of using existing data for qAOP development.

pharmacology and toxicology↗

bioRxiv2026

Deoxycholic Acid (DCA) a Secondary Bile Acid, Mitigates Ovariectomy-Induced Bone Loss and promotes Bone Healing: A Novel Candidate for Orthopaedic Applications

Introduction Postmenopausal osteoporosis (PMO) is a metabolic disorder, characterized by accelerated bone loss, gut microbiota (GM) dysbiosis and altered microbial metabolites. Deoxycholic acid (DCA) is a secondary bile acid with an FDA-approved drug status for submental fat treatment in adults; however its effect on bone health remains underexplored. Materials and Methods This study investigated the effects of DCA on bone health using both preclinical animal model of PMO and clinical samples from PMO women. DCA (20 mg/kg) was administered to ovariectomised (OVX) mice for 45 days, and its effects on bone microarchitecture and serum cytokines were analysed. Osteoclastogenesis and osteoblastogenesis were evaluated using murine and human samples. Untargeted and targeted metabolomics analyses were performed using an ultra-high-performance liquid chromatographic system coupled with high-resolution Orbitrap mass spectrometry (HRMS). Secondary analysis of 16S rRNA sequencing data was performed using R programming. Results GM analysis and plasma metabolomics revealed an alteration in bacterial taxa associated with secondary BA synthesis and reduced circulating DCA levels. DCA administration improved impaired trabecular and cortical bone microarchitecture in the OVX mice by inhibiting osteoclastogenesis and enhancing osteoblastogenesis. Moreover, DCA altered circulating osteoclastogenic (IL-6, Il-9, IL-17A, IFN-{gamma}, RANKL) and osteoblastogenic (OPG, TGF-{beta}, IL-10) factors. Mechanically, DCA suppressed osteoclast differentiation and the expression of genes associated with osteoclast formation (NFATC1, NFKB, TRAF6, TREM2, SYNB), fusion (CSF1R, DC-STAMP, CD47), and resorption (CTSK, ATP6VOD1, ATP6VOD2, CAR2, SPP1) in human peripheral blood mononuclear cells (PBMCs), while promoting osteogenic differentiation and matrix mineralization in bone marrow-derived mesenchymal stem cells (BMSCs) from PMO women. Additionally, DCA enhanced the nascent calcium deposition at the fracture site and improved bone healing via inhibiting osteoclastogenesis. Conclusion Overall, reduced DCA availability was associated with PMO, while DCA treatment mitigated OVX-induced bone loss and improved bone healing. This study highlights the therapeutic potential of DCA for maintaining both bone homeostasis in PMO and fracture healing with immense orthopaedic applications.

pharmacology and toxicology↗